miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42

Qingjiang Chen(First Affiliated Hospital of Zhengzhou University), Xinguang Cao(Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Xiaobing Chen(Zhengzhou University), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Suxia Luo(Zhengzhou University)
Digestive Diseases and Sciences
January 7, 2011
10.1007/s10620-010-1536-3
Cited by 140

Related Papers

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
|癌症：英文版|2021|207
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
|Journal of Hematology & Oncology|2018|134